Daily Stock Analysis, GAMR, Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia., priceseries

Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.. Daily Stock Analysis
Stock Information
Open
102.39
Close
101.70
High
102.39
Low
101.26
Previous Close
101.75
Daily Price Gain
-0.05
YTD High
120.65
YTD High Date
Jan 28, 2021
YTD Low
78.68
YTD Low Date
Jan 4, 2021
YTD Price Change
22.72
YTD Gain
28.76%
52 Week High
120.65
52 Week High Date
Jan 28, 2021
52 Week Low
44.75
52 Week Low Date
Apr 21, 2020
52 Week Price Change
55.46
52 Week Gain
119.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 24. 2017
33.71
Jun 12. 2017
39.15
34 Trading Days
16.14%
Link
LONG
May 4. 2018
46.50
Jun 12. 2018
51.16
26 Trading Days
10.01%
Link
LONG
Apr 8. 2020
43.07
May 1. 2020
45.63
16 Trading Days
5.94%
Link
LONG
May 5. 2020
46.65
May 27. 2020
50.12
15 Trading Days
7.43%
Link
LONG
Jun 15. 2020
53.61
Jul 16. 2020
59.27
22 Trading Days
10.55%
Link
LONG
Jul 29. 2020
60.76
Aug 11. 2020
64.16
9 Trading Days
5.59%
Link
LONG
Nov 13. 2020
69.19
Dec 10. 2020
73.77
18 Trading Days
6.62%
Link
LONG
Dec 14. 2020
75.49
Feb 2. 2021
93.04
33 Trading Days
23.25%
Link
LONG
Mar 8. 2021
90.73
Mar 17. 2021
96.05
7 Trading Days
5.86%
Link
Company Information
Stock Symbol
GAMR
Exchange
NASDAQ
Company URL
http://www.galectintherapeutics.com
Company Phone
678-620-3186
CEO
Peter G. Traber
Headquarters
Georgia
Business Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA 30071
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001133416
About

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.